Literature DB >> 11214776

Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study.

F Schindel1.   

Abstract

OBJECTIVE: The pharmacokinetic analysis of biologic compounds is frequently disturbed by the presence of endogenous levels, which cannot be discerned from exogenous levels. The frequently used method of subtracting baseline levels from subsequent measurements was compared to a fully adjusted regression model in a simulation study.
METHODS: Simulations (5,000 each) were carried out for a standard one-compartment model with rich (n = 10) and poor (n = 6) postdose sampling, using unweighted as well as two-weighted types of non-linear regression.
RESULTS: Whereas the fully adjusted model performed properly across various scenarios, the subtraction method showed a noteworthy bias (up to 14%) for area under the curve (AUC) and elimination half-life with weighted non-linear regression. For estimation of the Cmax parameter using any weighting scheme, and of any parameter using unweighted non-linear regression, the two methods performed equally well. As expected, poor in contrast to rich sampling resulted in larger coefficients of variation, but also in increasing failures (4.4%) of the regression algorithm (failure to converge, negative Cmax or half-life) for the subtraction method when it was combined with the weighting scheme giving highest weight to small concentrations.
CONCLUSION: The risk of biased results may result from the subtraction method, which may also affect the analysis of dose linearity, bioequivalence and population kinetic studies with biologic compounds. When background endogenous levels are not negligible, a fully adjusted model is recommended.

Mesh:

Year:  2000        PMID: 11214776     DOI: 10.1007/s002280000230

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.

Authors:  Akashi Togawa; Takanori Tanaka; Satoru Nagashima; Hiroyuki Keta; Yasue Kobayashi; Yasuhiro Nishikawa; Masanobu Yanai; Hideji Tanaka
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 2.  Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design.

Authors:  Sanjeeva Dissanayake
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

4.  Adjustment of endogenous concentrations in pharmacokinetic modeling.

Authors:  Alexander Bauer; Martin J Wolfsegger
Journal:  Eur J Clin Pharmacol       Date:  2014-10-03       Impact factor: 2.953

5.  Methods of utilizing baseline values for indirect response models.

Authors:  Sukyung Woo; Dipti Pawaskar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-21       Impact factor: 2.745

6.  Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Authors:  Donald J Irby; Mustafa E Ibrahim; Anees M Dauki; Mohamed A Badawi; Sílvia M Illamola; Mingqing Chen; Yuhuan Wang; Xiaoxi Liu; Mitch A Phelps; Diane R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.